Chemours (NYSE:CC) Insider Calderon Gerardo Familiar Buys 1,935 Shares of Stock

The Chemours Company (NYSE:CC) insider Calderon Gerardo Familiar bought 1,935 shares of the stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average price of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the purchase, the insider directly owned 58,547 shares in the company, valued at approximately $909,234.91. This trade represents a 3.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Chemours Price Performance

CC opened at $15.23 on Friday. The firm has a market cap of $2.29 billion, a P/E ratio of -7.97 and a beta of 1.43. The firm has a 50-day moving average of $18.63 and a 200 day moving average of $20.03. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. The Chemours Company has a fifty-two week low of $10.44 and a fifty-two week high of $28.67.

Chemours (NYSE:CC) last announced its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.07). The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.65 billion. Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.The business’s revenue was down 1.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.54) EPS. On average, research analysts expect that The Chemours Company will post 0.88 EPS for the current year.

Chemours Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.0875 per share. The ex-dividend date is Friday, August 14th. This represents a $0.35 annualized dividend and a dividend yield of 2.3%. Chemours’s dividend payout ratio (DPR) is presently -18.32%.

Trending Headlines about Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: CEO Denise Dignam purchased 3,378 shares at an average price of $14.95, investing approximately $50,500 and increasing her ownership by 1%. SEC filing on Denise Dignam’s purchase
• Positive Sentiment: Insider Gerardo Familiar Calderon bought 1,935 shares at an average price of $15.53, spending about $30,000 and increasing his stake by 3.42%. The purchases may signal that insiders view the recent weakness as an opportunity. SEC filing on Gerardo Familiar Calderon’s purchase
• Neutral Sentiment: BMO Capital Markets reduced its price target from $26 to $18 but maintained an “outperform” rating. The revised target still implies meaningful upside, although the cut reflects lower near-term expectations. The Fly report on BMO’s Chemours rating
• Negative Sentiment: JPMorgan lowered its price target from $22 to $15 and retained a “neutral” rating, placing its target roughly in line with the current share price and reducing support for a near-term rebound. Benzinga report on JPMorgan’s Chemours rating
• Negative Sentiment: Zacks Research downgraded Chemours from “strong buy” to “strong sell,” adding the most bearish analyst signal among the recent updates. Zacks Research report on Chemours

Analyst Upgrades and Downgrades

Several research firms recently commented on CC. Alembic Global Advisors reiterated an “overweight” rating and issued a $30.00 price objective on shares of Chemours in a research note on Wednesday, May 13th. Mizuho set a $22.00 target price on Chemours in a research report on Wednesday, August 5th. Truist Financial lowered their target price on Chemours from $30.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. UBS Group reaffirmed a “neutral” rating and set a $18.00 price target (down from $29.00) on shares of Chemours in a research report on Monday. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $17.00 price target on shares of Chemours in a research note on Thursday. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Chemours has a consensus rating of “Hold” and a consensus price target of $20.10.

Institutional Investors Weigh In On Chemours

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Chemours in the second quarter worth $477,769,000. Cooper Creek Partners Management LLC purchased a new stake in Chemours during the 3rd quarter worth about $63,103,000. Wolf Hill Capital Management LP purchased a new stake in Chemours during the 2nd quarter worth about $59,698,056,000. Bank of New York Mellon Corp purchased a new stake in Chemours during the 2nd quarter worth about $33,353,000. Finally, Scopia Capital Management LP boosted its stake in Chemours by 71.7% in the 2nd quarter. Scopia Capital Management LP now owns 3,355,261 shares of the specialty chemicals company’s stock worth $38,418,000 after purchasing an additional 1,401,539 shares during the period. Hedge funds and other institutional investors own 76.26% of the company’s stock.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.